Takeda to take back Prostap in the UK and Ireland
This article was originally published in Scrip
Takeda is to take over the marketing of Prostap (sustained-release leuprorelin acetate) in the UK and Ireland later this year following the expiry of a long-standing licence agreement with Wyeth.
You may also be interested in...
Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.
Cancer deals involving Junshi/Wigen, Allist/Octimet, Yufan/Abound, Takeda/Presage, Daiichi Sankyo/AnHeart, LegoChem/Harbour Biomed, plus a stem cell partnership and a lysosomal storage disorder agreement.
Japan coordinates initiative to improve regional early-stage development of novel cancer therapies, which will work both with the industry and independently to improve access.